• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu


Record of Telephone Conversation, October 19, 2011 - MenHibrix

Product:  MenHibrix

Manufacturer:   GSK          

Telecon Date/Time:  19 OCT 2011           Initiated by FDA?  Yes
Telephone Number: -----(b)(4)-----

Communication Categorie(s): Information Request

Author:  Tina Roecklein

Telecon Summary:
Additional information to finish review

FDA Participants:  
Tina Roecklein

Non-FDA Participants:   

Jody Gould

Telecon Body:

GSK submitted their response to our 11 June 2010 CR letter on 15 April 2011.  A second CR letter was sent to GSK on 22 September 2011.  Two items were noted during the review that did not meet the criteria for inclusion in the CR letter.  I called the firm to request the additional information below.

  1. The updated validation report for the MenY SBA dated August 2010 has a “confidential” watermark that obscures part of every page.  Please submit a clean copy of the report for review.

    Report Name:  Measurement of bactericidal activity of human serum antibodies to Neisseria meningitidis Serogroup Y in presence of human complement

    Edition date:  August 2010

    No. Code:  2009-V-008-R

  2. Figure 5 on page 19 of the CR response dated 15 April 2011 for Question 38 is a graph of Linearity for ---(b)(4)--- and ---(b)(4)--- Content.  These tests are plotted on the same graph and the resultant ---(b)(4)--- Plot encompasses the entire graph while the ---(b)(4)--- line is only a small portion of the graph.  Please replot the ---(b)(4)--- data so that the line will use the entire graph so that any possible trends could be detected.